Research
Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss (15-23%) and should be considered for patients with higher weight-loss goals or specific comorbidities like MASH or severe OSA.
If you have obesity and related health issues like sleep apnea or fatty liver, your doctor might recommend injectable medications like semaglutide or tirzepatide. These can lead to significant weight loss (15-23%) when combined with lifestyle changes. Discuss the pros and cons of injectable vs. oral options with your provider.
StrongSupportsHIGH confidence
For these patients, obesity medication such as weekly injectable semaglutide or tirzepatide that produce 17% to 23% reductions in body weight may be more appropriate.
Why this rating
Based on multiple RCTs cited in the review.
Source
Obesity: assessment and treatment across the care continuum
Robert F. Kushner et al. · Annals of Medicine · 2025
narrative_reviewCited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →